Join
Live feed
·
PRReleasevia Quantisnow
Ocular Therapeutix Inc. logo

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

ByQuantisnow·Wall Street's wire, on your screen.
OCUL· Ocular Therapeutix Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OCUL (Ocular Therapeutix Inc.) and more on Quantisnow.